seri
indolebas
spirothiazolidinon
design
synthes
evalu
vitro
antitubercular
antivir
antibacteri
antifung
activ
structur
new
compound
establish
ir
h
nmr
c
nmr
proton
decoupl
apt
dept
electrospray
ioniz
mass
spectrometri
microanalysi
compound
bear
phenyl
substitu
posit
spiro
ring
exhibit
signific
antitubercular
activ
mycobacterium
tuberculosi
atcc
concentr
still
test
compound
display
activ
mycobacteria
mic
valu
four
indolespirothiazolidinon
deriv
found
moder
activ
punta
toro
viru
yellow
fever
viru
sindbi
viru
vero
cell
antivir
ec
valu
rang
select
index
ratio
cytotox
antivir
effect
concentr
case
potent
effect
seen
compound
methyl
posit
spirothiazolidinon
system
graphic
abstract
tuberculosi
tb
highli
infecti
diseas
caus
bacillu
mycobacterium
tuberculosi
past
year
lead
caus
mortal
electron
supplementari
materi
onlin
version
articl
http
contain
supplementari
materi
avail
author
user
singl
infecti
diseas
rank
hivaid
major
problem
associ
current
avail
tb
treatment
includ
long
treatment
durat
inadequ
complianc
concurr
hiv
infect
increas
incid
multidrugresist
mdr
extens
drugresist
xdr
tuberculosi
emerg
difficult
treat
strain
necessit
discoveri
develop
novel
antitubercular
drug
domain
inact
sever
decad
two
new
drug
becam
avail
ie
mitochondri
atp
synthas
inhibitor
bedaquilin
mycol
acid
biosynthesi
inhibitor
delamanid
receiv
acceler
approv
treatment
mdr
tuberculosi
respect
besid
divers
novel
drug
candid
preclin
clinic
develop
incorpor
alicycl
system
fig
extens
studi
differ
research
group
type
compound
found
highli
activ
drugsuscept
drugresist
strain
mycobacterium
tuberculosi
act
transport
protein
previou
investig
identifi
indolespirothiazolidinon
system
fig
promis
scaffold
mycobacterium
tuberculosi
strain
analogu
exhibit
vitro
antitubercular
activ
gi
growth
inhibit
valu
mic
minimum
inhibitori
concentr
valu
recent
report
synthesi
novel
deriv
contain
nucleu
instead
spirothiazolidinon
system
two
molecul
fig
display
notabl
antitubercular
activ
concentr
tenfold
lower
produc
cytotox
mammalian
cell
line
furthermor
sever
spirothiazolidinon
compound
synthes
laboratori
found
effici
inhibitor
membran
fusion
mediat
influenza
viru
hemagglutinin
ha
demonstr
fig
compound
similar
backbon
structur
consist
aromaticpolycycl
ring
link
nonaromat
spiro
system
via
amid
bridg
analogu
display
low
micromolar
activ
influenza
subtyp
favor
select
index
base
insight
object
optim
antimicrobi
activ
indolyl
thiazolidinon
spirothiazolidinon
report
chemic
synthesi
structur
character
vitro
antitubercular
antivir
antibacteri
antifung
evalu
new
nonan
fig
synthet
pathway
prepar
spirothiazolidinon
illustr
scheme
thu
diazonium
salt
form
reaction
nano
hcl
react
ethyl
obtain
compound
accord
jappklingemann
reaction
fischer
indol
synthesi
carri
acid
medium
cycliz
ethyl
subsequ
exposur
excess
hydrazin
hydrat
afford
compound
target
spirocycl
compound
synthes
treatment
key
intermedi
appropri
cyclic
keton
mercapto
acid
onepot
reaction
structur
new
compound
character
ir
h
nmr
c
nmr
proton
decoupl
apt
dept
electrospray
ioniz
mass
spectrometri
esim
combust
analysi
ir
spectra
exhibit
ring
exocycl
co
band
cm
cm
respect
shift
observ
amid
band
compar
cm
presenc
addit
lactam
band
provid
definit
proof
aim
cycliz
observ
nh
signal
assign
indol
nh
ppm
amid
nh
ppm
togeth
absenc
nh
reson
intermedi
hydrazid
h
nmr
spectra
provid
evid
format
new
adduct
sch
sch
proton
newli
form
spiroalkan
residu
reson
ppm
respect
sch
proton
appear
singlet
except
methylen
hydrogen
compound
observ
separ
doublet
larg
coupl
constant
j
hz
due
gemin
coupl
result
chiral
center
spirothiazolidinon
ring
h
nmr
spectra
display
thiazolidinon
sch
proton
quartet
broaddistort
singlet
doublet
assign
indol
proton
achiev
basi
valu
coupl
constant
report
indol
ring
carbon
reson
assign
chemic
shift
comparison
previous
report
c
nmr
data
compound
similar
backbon
structur
ch
ch
ch
c
signal
assign
antitubercular
activ
compound
test
vitro
tuberculosi
atcc
use
microdilut
method
lowest
concentr
compound
inhibit
mycobacteri
growth
cultur
defin
mic
rifampicin
use
refer
drug
compound
assay
use
twofold
dilut
start
shown
tabl
compound
h
bear
phenyl
substitu
posit
spiro
ring
exhibit
highest
antitb
activ
concentr
respect
compound
seri
display
activ
mycobacteria
mic
valu
look
chemic
structur
activ
compound
observ
presenc
methyl
group
posit
spirocycl
system
seri
led
signific
reduct
antitubercular
activ
introduct
bulki
aromat
substitu
c
h
posit
ring
enhanc
antitubercular
activ
compound
evalu
varieti
dna
rna
virus
cell
cultur
name
herp
simplex
viru
acyclovirresist
thymidin
kinasedefici
tk
mutant
vaccinia
viru
human
human
coronaviru
vesicular
stomat
viru
coxsacki
viru
respiratori
syncyti
viru
viru
reoviru
sindbi
viru
punta
toro
viru
yellow
fever
viru
influenza
influenza
b
viru
cytopath
effect
reduct
assay
reveal
compound
moder
activ
punta
toro
viru
yellow
fever
viru
sindbi
viru
vero
cell
tabl
antivir
ec
valu
rang
select
index
si
ratio
cytotox
antivir
effect
concentr
case
see
valu
bracket
tabl
potent
effect
seen
compound
methyl
posit
spirothiazolidinon
system
note
antivir
activ
obtain
analogu
carri
spirofus
cyclopentan
ring
instead
cyclohexan
ie
bulkier
group
methyl
cyclohexan
residu
introduct
methyl
group
posit
ring
system
eg
compar
compound
seem
slightli
posit
effect
antivir
activ
test
compound
exhibit
activ
dnaor
rnavirus
test
nevertheless
broad
antivir
test
allow
determin
compound
cytotox
activ
differ
mammalian
cell
line
tabl
gener
compound
endow
antivir
activ
tend
less
cytotox
inact
deriv
broad
antibacteri
antifung
activ
compound
h
assess
use
experi
perform
twice
result
obtain
mic
actual
minimum
inhibitori
concentr
requir
inhibit
growth
organ
search
effect
antimicrobi
agent
achiev
synthesi
novel
spirothiazolidinon
deriv
scaffold
structur
new
compound
character
confirm
spectrometr
method
ir
h
nmr
c
nmr
esim
element
analysi
compound
evalu
vitro
antitubercular
antivir
antibacteri
antifung
activ
variou
viral
bacteri
fungal
strain
compound
bear
bulki
phenyl
group
posit
spiro
ring
display
appreci
antitb
activ
tuberculosi
atcc
mic
valu
respect
compound
exhibit
inhibitori
effect
replic
punta
toro
viru
yellow
fever
viru
sindbi
viru
vero
cell
antivir
ec
valu
rang
select
index
si
ratio
cytotox
antivir
effect
concentr
case
potent
effect
seen
compound
methyl
posit
spirothiazolidinon
system
neither
indolespirothiazolidinon
compound
show
activ
bacteri
fungal
strain
test
concentr
purchas
solvent
chemic
analyt
grade
use
receiv
melt
point
determin
open
capillari
tube
buchi
melt
point
apparatu
microanalys
perform
thermo
mixtur
mol
appropri
cyclohexanonecyclopentanon
mol
mercaptoacet
acid
acid
mol
cm
dri
toluen
heat
reflux
heat
mantl
h
use
deanstark
water
separ
excess
toluen
evapor
vacuo
result
residu
treat
satur
nahco
solut
co
evolut
ceas
allow
stand
overnight
case
refriger
solidif
solid
thu
obtain
wash
water
dri
recrystal
ethanol
ethyl
acet
n
microdilut
method
perform
accord
standard
protocol
clinic
laboratori
standard
institut
clsi
resazurin
microtitr
assay
rema
develop
colorimetr
standard
method
drug
suscept
test
minimum
inhibitori
concentr
mic
determin
accord
color
chang
end
incub
strain
use
ie
mycobacterium
tuberculosi
atcc
suscept
common
antimycobacteri
drug
middlebrook
broth
medium
becton
dickinson
usa
use
medium
adjust
ph
bottl
control
steril
use
resazurin
purchas
sigmaaldrich
st
loui
usa
dissolv
steril
distil
water
final
concentr
steril
filtrat
store
use
rifampicin
purchas
bectondickinson
bd
usa
dissolv
steril
distil
water
final
concentr
critic
concentr
synthes
compound
dissolv
dimethyl
sulfoxid
accord
clsi
method
stock
solut
obtain
dilut
dmso
follow
steril
filtrat
work
stock
obtain
dilut
medium
final
concentr
synthes
compound
rifampicin
critic
concentr
cm
use
inoculum
suspens
mycobacteria
prepar
accord
clsi
guidelin
describ
previous
isol
subcultur
jensen
medium
incub
day
coloni
freshli
grown
tuberculosi
suspend
middlebrook
broth
medium
obtain
mcfarland
turbid
dilut
ten
time
medium
broth
microdilut
test
perform
steril
ushap
microdilut
plate
lp
italiano
spa
milano
itali
row
af
contain
mm
compound
dilut
wherea
row
g
posit
control
h
neg
control
contain
mm
medium
one
hundr
mm
correspond
inoculum
ad
well
except
row
h
micropl
incub
day
mycobacteri
growth
clearli
visibl
white
sediment
posit
control
microbi
growth
confirm
ehrlichziehlneelsen
acidfast
stain
resazurin
solut
mm
ad
well
plate
incub
one
addit
day
time
first
purpl
color
well
growth
visibl
defin
compound
mic
valu
tabl
stock
solut
test
refer
compound
prepar
dmso
mm
incub
cell
highest
test
concentr
ribavirin
antivir
refer
compound
ganciclovir
brivudin
zanamivir
amantadin
ribavirin
dextran
mycophenol
acid
antivir
evalu
carri
broad
panel
virus
use
cytopath
effect
cpe
reduct
assay
human
influenza
b
virus
examin
madindarbi
canin
kidney
mdck
cell
respiratori
syncyti
viru
vesicular
stomat
viru
coxsacki
viru
evalu
human
cervix
carcinoma
hela
cell
african
green
monkey
vero
cell
use
viru
sindbi
viru
coxsacki
viru
punta
toro
viru
yellow
fever
viru
human
embryon
lung
hel
fibroblast
cell
infect
herp
simplex
viru
type
vaccinia
viru
human
human
coronaviru
semiconflu
cell
cultur
plate
infect
viru
multipl
infect
ccid
cell
cultur
infect
dose
per
well
togeth
viru
fourfold
dilut
test
refer
compound
ad
plate
incub
influenzaand
coronaviru
far
advanc
cpe
visibl
ie
day
day
case
microscopi
perform
score
cpe
calcul
antivir
effect
concentr
ec
microscopi
also
done
assess
cytotox
express
compound
concentr
caus
minim
chang
cell
morpholog
minim
cytotox
concentr
mcc
serial
twofold
dilut
rang
prepar
test
medium
ie
muellerhinton
broth
bacteria
medium
yeast
strain
inoculum
prepar
use
h
broth
cultur
bacteria
type
h
cultur
yeast
strain
adjust
turbid
equival
mcfarland
standard
dilut
broth
media
give
final
concentr
test
tray
cfucm
bacteria
cfucm
yeast
tray
cover
place
plastic
bag
prevent
evapor
bacteria
tray
incub
h
yeastcontain
tray
incub
h
mic
defin
lowest
concentr
compound
give
complet
inhibit
visibl
growth
amikacin
fluconazol
use
refer
antibiot
bacteria
yeast
respect
mic
valu
within
accuraci
rang
clsi
guidelin
